Article

Model-based comparisons of post-treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European Union

2024-05-23

Abstract excerpt

<h4>Aims: </h4>: Omalizumab is an anti-immunoglobulin E (IgE) monoclonal antibody that was first approved by the United States (US) Food and Drug Administration (FDA) for the treatment of allergic asthma in 2003. The pivotal trials supporting the initial approval of omalizumab used dosing determined by patient’s baseline IgE and body weight, with the goal of reducing the mean free IgE level to approximately 25 ng/...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: e7fd43e4-d191-5794-a412-96ab3bad0f57
DOI: 10.22541/au.171644032.24626469/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Model-based comparisons of post-treatment free IgE and FEV1 between omalizumab asthma dosing tables in the United States and European UnionDOI 10.22541/au.171644032.24626469/v1Read

Combined analytical assays for the characterization of drugs binding to human IgE: Applicability to omalizumab-bearing biosimilar candidates assessmentSemantic proximity Read

Mepolizumab real-world effectiveness in severe asthma with an eosinophilic phenotype and overlapping severe allergic asthma.Semantic proximity Read

Clinical Experience with Anti-IgE Monoclonal Antibody (Omalizumab) In Paediatric Severe Allergic Asthma – A Romanian PerspectiveSemantic proximity Read

Omalizumab for the Treatment of Allergic Rhinitis: A Systematic Review and Meta-AnalysisSemantic proximity Read

Effect of Specific Immunoglobulin E Response and Comorbidities on Effectiveness of MP-AzeFlu in a Real-Life Study.Semantic proximity Read

Structural basis of omalizumab therapy and omalizumab-mediated IgE exchange.Semantic proximity Read

The anti-IgE mAb omalizumab induces adverse reactions by engaging Fcγ receptors.Semantic proximity Read

Structural and Physical Basis for Anti-IgE Therapy.Semantic proximity Read

Efficacy and Safety of Add-On Omalizumab in 4-6-Year-Old Children with Uncontrolled Allergic Asthma: A 52-Week Retrospective StudySemantic proximity Read

Pros and cons: Should AIT be considered in all patients with allergic asthma?Semantic proximity Read

Application of stochastic simulation-estimation approach to the optimization of Pharmacokinetic studies design in the context of paediatric extrapolation: A step toward better decision making for drug sponsors and regulatorsSemantic proximity Read

Pharmacokinetic /Pharmacodynamic Considerations of Alternate Dosing Strategies of Tocilizumab in COVID-19Semantic proximity Read